vTv Therapeutics Inc (NASDAQ:VTVT) Announces Its Second Quarter Financial Results

1220
Drugs Tablets Pain Medication Pills Headache

vTv Therapeutics Inc (NASDAQ:VTVT) is a clinical stage pharmaceutical business that focuses on the development of solutions for unmet medical needs. The company unveiled its second quarter financial results for June 30, 2018 today. Asides from that, it has also given updates regarding the upcoming events as well as its most recent achievements.

Current state of affairs

The current chief executive officer of vTv Therapeutics Steve Holcombe opined, “Since our announcement regarding the topline results from Part B of the STEADFAST Study, we have continued to analyze the results from Parts A and B and are encouraged by our findings.”

Holcombe outlined that the rest of their programs were at the moment in their clinical development. The goal is to handle the type 1 diabetes in the most amicable way. The company struck collaboration with Huadong Medicine and the two are now pushing the GLP-1R program and the target is to face out type 2 diabetes.

The turn of events

Holcombe spoke in relation to diabetes, Alzheimer’s disease and the various inflammatory disorders terming them treatable. The official said that they were looking into long-term solutions that would save patients from the major discomfort.

Both the FDA and the scientific advisory board are major players that can help a huge deal in taking the development of the therapy to highest possible levels. The Azeliragon data analysis is still on course and the company seeks to realize the most impressive outcome in the near future.

The Simplic T-1 study is out to enroll a significant number of patients struggling with type 1 diabetes. The company reveals that the adaptive Phase 1/2 SimplicT-1 Study is at this point giving dosages to patients. It seeks to evaluate the effect of TTP399 as an add-on to insulin therapy and that study will go on for 12 weeks.

TTP399 has in recent studies showcased remarkable abilities in reducing HbA1c levels. The AGATA Study was one of them and its will help a huge deal in the fight against type 2 diabetes.

The company also seeks to advance its PDE4 program with Newsoara and this will take place in the course of the second quarter.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.